Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.

Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.

Abstract: Subject of the present invention are biomarkers and methods for the identification of risk for subsequent cardiovascular event (e.g. coronary heart disease death, non-fatal myocardial infarction, ischemic stroke, hospitalizations for unstable angina pectotis, cardiac arrest) in patients that have experienced an acute coronary syndrome, comprising the detecting the level of NT-proBNP, homocysteine and CRP.

Abstract: Systems and methods for diagnosing acute kidney injury following an acute event or surgical intervention, based on assessing the biomarker L-FABP. Also, systems and methods for predicting the risk of an individual to suffer from a kidney injury after an acute event or surgical intervention in the future.

Abstract: Systems and methods for diagnosing acute kidney injury following an acute event or surgical intervention, based on assessing the biomarker L-FABP. Also, systems and methods for predicting the risk of an individual to suffer from a kidney injury after an acute event or surgical intervention in the future.

Abstract: The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of H-FABP and, optionally, myoglobin in a sample of the subject and comparing the amount of H-FABP and, optionally, myoglobin to reference amounts.

Abstract: Disclosed is a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level, which is detectable, but lower than the level that is considered as being indicative for a myocardial infarction. Also disclosed is a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable, but lower than a level that is considered as being indicative for a myocardial infarction. These methods are based on the determination of myoglobin and, optionally, Heart-type fatty acid binding protein (H-FABP) in a sample of the subject and comparing the amount of myoglobin and, optionally, H-FABP to reference amounts. Also disclosed are kits or devices to carry out the methods.

Abstract: The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level, which is detectable, but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable, but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of myoglobin and, optionally, Heart-type fatty acid binding protein (H-FABP) in a sample of said subject and comparing the amount of myoglobin and, optionally, H-FABP to reference amounts. Also comprised by the present invention are kits or devices to carry out the methods of the present invention.

Abstract: The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of H-FABP and, optionally, myoglobin in a sample of the subject and comparing the amount of H-FABP and, optionally, myoglobin to reference amounts.

Abstract: Methods for measurement of at least one advanced glycation endproduct (AGE) in a cerebrospinal fluid (CSF) sample and use of these methods in the assessment of neurodegenerative disease.

Abstract: The invention concerns monoclonal antibodies against a complex of human ACT and a serine protease, preferably against a ACT-PSA, which have essentially no cross-reactivity with free, non-complexed human ACT and with free, non-complexed PSA, as well as diagnostic test methods for detecting serine protease-ACT complexes, in particular PSA-ACT, using these monoclonal antibodies.

Abstract: The invention concerns monoclonal antibodies against a complex of human ACT and a serine protease, preferably against a ACT-PSA, which have essentially no cross-reactivity with free, non-complexed human ACT and with free, non-complexed PSA, as well as diagnostic test methods for detecting serine protease-ACT complexes, in particular PSA-ACT, using these monoclonal antibodies.

Abstract: The present invention relates to the field of detection and measurement of advanced glycosylation endproducts (AGEs), in particular to methods of selection and/or quality control of a reagent or a coated solid phase component appropriate for AGE-assays. It also relates to a process for production of an AGE-free solid phase component, the solid phase component, and to the use of such solid phase component.

Abstract: For the immunological determination of PSA-ACT complexes in a sample to be examined in which the sample is contacted with at least one antibody that specifically binds the complexes or their components or with specifically binding fragments thereof in which the antibody is bound to a solid phase or can be bound to a solid phase, a test liquid is used according to the invention which contains 0.5 to 2.5 mol/l of an alkali chloride at least during contact between the sample and the solid phase. A buffer system according to the invention for a PSA-ACT test contains 0.5 to 2.5 mol/l, preferably 1.5 to 2.0 mol/l alkali chloride in addition to other common buffer substances.

Abstract: The invention concerns human monoclonal antibodies of the IgG isotype against human pancreatic islet cells which can be obtained by immortalizing human lymphocytes of prediabetics or diabetics, treating the culture supernatant of the immortalized cells with a conjugate of antibodies against human Fc &ggr; and a label, subsequently treating with human immunoglobulin, incubating with immobilized human pancreatic islet cells identifying an immortalized human cell culture which produces an antibody against pancreatic islet cells via determination of the label bound to the immobilized islet cells, isolating a human immortalized cell which produces this antibody, propagating this immortalized cell and isolating the monoclonal antibody produced by these cells. The invention also concerns a process for the isolation of an islet cell antigen to which such antibodies bind as well as a method for the determination of antibodies against an islet cell antigen of the pancreas.

Abstract: The invention concerns human monoclonal antibodies of the IgG isotype against human pancreatic islet cells which can be obtained by immortalizing human lymphocytes of prediabetics or diabetics, treating the culture supernatant of the immortalized cells with a conjugate of antibodies against human Fc .gamma. and a label, subsequently treating with human immunoglobulin, incubating with immobilized human pancreatic islet cells identifying an immortalized human cell culture which produces an antibody against pancreatic islet cells via determination of the label bound to the immobilized islet cells, isolating a human immortalized cell which produces this antibody, propagating this immortalized cell and isolating the monoclonal antibody produced by these cells.The invention also concerns a process for the isolation of an islet cell antigen to which such antibodies bind as well as a method for the determination of antibodies against an islet cell antigen of the pancreas.

Abstract: The invention concerns interference-eliminating agents for avoiding unspecific interactions in immunoassays in which avidin or streptavidin or a derivative thereof are used as the interference-eliminating agents.

Abstract: The present invention provides a process for the determination of an antibody in human body fluids according to the immunoassay principle in which a sample containing the antibody to be determined is incubated with at least two different receptors R.sub.1 and R.sub.2, of which one receptor R.sub.1 carries an antigenic determinant specific for the antibody to be determined and one receptor R.sub.2 carries a label to form bound and unbound label, the part which contains the bound label is separated from the part which contains the unbound label and the label is measured in one of the two parts, wherein, for the control, instead of the sample, there is used a standard solution which contains a conjugate of a bindable non-human antibody or a Fab or F(ab').sub.2 fragment thereof which non-human component binds with a receptor R.sub.s which also binds to the antibody to be determined, and a human immunoglobulin or the Fc part thereof.